+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biomarkers Market Size, Share & Trends Analysis Report by Type (Efficacy, Validation), Product, Application (Drug Discovery & Development, Personalized Medicine), Disease, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 150 Pages
  • January 2024
  • Region: Global
  • Grand View Research
  • ID: 5450251
Description Jump to:
The global biomarkers market is expected to reach USD 194.21 billion by 2030, registering a CAGR of 13.36% from 2024 to 2030. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck’s immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company’s recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Biomarkers Market Report Highlights

  • The safety segment held the largest revenue share of 37.62% in 2023 owing to the increased adoption of safety biomarkers in drug discovery and development
  • The efficacy biomarkers segment is expected to grow at the fastest CAGR from 2024 to 2030 due to a rise in strategic collaborations for promoting research activities
  • The drug discovery & development segment dominated the market in 2023 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
  • The cancer segment led the market in 2023 and is expected to retain its dominance from 2024 to 2030.. However, the neurological diseases segment is anticipated to record the fastest CAGR over the forecast years
  • Asia-Pacific is anticipated to attain the fastest CAGR from 2024 to 2030 due to the rising investments by key players and increasing disease prevalence in the region

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Product
1.2.3. Application
1.2.4. Disease
1.2.5. Regional Scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.5.1. Data for Primary Interviews in North America
1.4.5.2. Data for Primary Interviews in Europe
1.4.5.3. Data for Primary Interviews in Asia-Pacific
1.4.5.4. Data for Primary Interviews in Latin America
1.4.5.5. Data for Primary Interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type and product outlook
2.2.2. Application and disease outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Biomarkers Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing funding for biomarkers
3.2.1.2. Increasing prevalence for chronic diseases
3.2.1.3. Technological advancement
3.2.1.4. Growing importance of companion diagnostics
3.2.2. Market restraint analysis
3.2.2.1. Lack of reimbursement policies for biomarkers
3.2.2.2. High capital investment and lengthy timelines for biomarker development
3.2.3. Market opportunity analysis
3.2.3.1. Emergence of personalized medicine
3.2.3.2. Emerging economies
3.2.4. Market challenge analysis
3.2.4.1. Challenges associated with biomarkers validation
3.2.4.2. Technical issues related to sample collection and storage
3.3. Biomarkers Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.3.1. Selling price of biomarker by top players
Chapter 4. Biomarkers Market: Type Estimates & Trend Analysis
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Biomarkers Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Safety biomarkers
4.4.1.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Efficacy biomarkers
4.4.2.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Predictive biomarkers
4.4.3.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Surrogate biomarkers
4.4.4.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. Pharmacodynamic biomarkers
4.4.5.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
4.4.6. Prognostics biomarkers
4.4.6.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.7. Validation biomarkers
4.4.7.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Biomarkers Market: Product Estimates & Trend Analysis
5.1. Product Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Biomarkers Market by Product Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Consumables
5.4.1.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Services
5.4.2.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. Software
5.4.3.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis
6.1. Application Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Biomarkers Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Diagnostics
6.4.1.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Drug Discovery and Development
6.4.2.1. Drug discovery and development market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Personalized Medicine
6.4.3.1. Personalized medicine market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. Disease Risk Assessment
6.4.4.1. Disease risk assessment market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5. Others
6.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis
7.1. Disease Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Biomarkers Market by Disease Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Cancer
7.4.1.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.2. Safety biomarkers
7.4.1.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.3. Efficacy biomarkers
7.4.1.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.4. Predictive biomarkers
7.4.1.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.5. Surrogate biomarkers
7.4.1.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.6. Pharmacodynamic biomarkers
7.4.1.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.7. Prognostics biomarkers
7.4.1.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.1.8. Validation biomarkers
7.4.1.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2. Cardiovascular Diseases
7.4.2.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2.2. Safety biomarkers
7.4.2.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2.3. Efficacy biomarkers
7.4.2.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2.4. Predictive biomarkers
7.4.2.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2.5. Surrogate biomarkers
7.4.2.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2.6. Pharmacodynamic biomarkers
7.4.2.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2.7. Prognostics biomarkers
7.4.2.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2.8. Validation biomarkers
7.4.2.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)Neurological Diseases
7.4.3.1. Neurological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3.2. Safety biomarkers
7.4.3.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3.3. Efficacy biomarkers
7.4.3.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3.4. Predictive biomarkers
7.4.3.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3.5. Surrogate biomarkers
7.4.3.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3.6. Pharmacodynamic biomarkers
7.4.3.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3.7. Prognostics biomarkers
7.4.3.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3.8. Validation biomarkers
7.4.3.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4. Immunological Diseases
7.4.4.1. Immunological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4.2. Safety biomarkers
7.4.4.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4.3. Efficacy biomarkers
7.4.4.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4.4. Predictive biomarkers
7.4.4.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4.5. Surrogate biomarkers
7.4.4.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4.6. Pharmacodynamic biomarkers
7.4.4.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4.7. Prognostics biomarkers
7.4.4.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4.8. Validation biomarkers
7.4.4.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5. Others
7.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5.2. Safety biomarkers
7.4.5.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5.3. Efficacy biomarkers
7.4.5.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5.4. Predictive biomarkers
7.4.5.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5.5. Surrogate biomarkers
7.4.5.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5.6. Pharmacodynamic biomarkers
7.4.5.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5.7. Prognostics biomarkers
7.4.5.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5.8. Validation biomarkers
7.4.5.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Biomarkers Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
8.5.1. U.S.
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.2. Canada
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
8.6. Europe
8.6.1. UK
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.2. Germany
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.3. France
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.4. Italy
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.5. Spain
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.6. Norway
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/ reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.7. Sweden
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework/ reimbursement structure
8.6.7.3. Competitive scenario
8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.8. Denmark
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework/ reimbursement structure
8.6.8.3. Competitive scenario
8.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
8.7. Asia-Pacific
8.7.1. Japan
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.2. China
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.3. India
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.4. Australia
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.5. South Korea
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ reimbursement structure
8.7.5.3. Competitive scenario
8.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.6. Thailand
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ reimbursement structure
8.7.6.3. Competitive scenario
8.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
8.8.2. Mexico
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ reimbursement structure
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
8.9. MEA
8.9.1. South Africa
8.9.1.1. Key country dynamics
8.9.1.2. Regulatory framework/ reimbursement structure
8.9.1.3. Competitive scenario
8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
8.9.2. Saudi Arabia
8.9.2.1. Key Country Dynamics
8.9.2.2. Regulatory framework/ reimbursement structure
8.9.2.3. Competitive scenario
8.9.2.4. Saudi Arabia market estimates and forecasts for 2018 to 2030 (USD Million)
8.9.3. UAE
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ reimbursement structure
8.9.3.3. Competitive scenario
8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
8.9.4. Kuwait
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ reimbursement structure
8.9.4.3. Competitive scenario
8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, by Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. F. Hoffmann-La Roche Ltd.
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Abbott
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Epigenomics AG
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. General Electric
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Johnson & Johnson Services, Inc.
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Thermo Fisher Scientific Inc.
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Bio-Rad Laboratories, Inc.
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Siemens Healthineers AG
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. QIAGEN
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. Merck KGaA
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives
9.3.14. PerkinElmer Inc.
9.3.14.1. Company overview
9.3.14.2. Financial performance
9.3.14.3. Product benchmarking
9.3.14.4. Strategic initiatives
9.3.15. Agilent Technologies, Inc.
9.3.15.1. Company overview
9.3.15.2. Financial performance
9.3.15.3. Product benchmarking
9.3.15.4. Strategic initiatives
9.3.16. Eurofins Scientific
9.3.16.1. Company overview
9.3.16.2. Financial performance
9.3.16.3. Product benchmarking
9.3.16.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 North America Biomarkers Market, By Country, 2018-2030 (USD Million)
Table 4 North America Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 5 North America Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 6 North America Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 7 North America Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 8 U.S. Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 9 U.S. Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 10 U.S. Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 11 U.S. Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 12 Canada Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 13 Canada Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 14 Canada Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 15 Canada Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 16 Europe Biomarkers Market, By Country, 2018-2030 (USD Million)
Table 17 Europe Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 18 Europe Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 19 Europe Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 20 Europe Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 21 Germany Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 22 Germany Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 23 Germany Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 24 Germany Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 25 UK Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 26 UK Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 27 UK Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 28 UK Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 29 France Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 30 France Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 31 France Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 32 France Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 33 Spain Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 34 Spain Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 35 Spain Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 36 Spain Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 37 Italy Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 38 Italy Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 39 Italy Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 40 Italy Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 41 Denmark Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 42 Denmark Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 43 Denmark Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 44 Denmark Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 45 Norway Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 46 Norway Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 47 Norway Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 48 Norway Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 49 Sweden Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 50 Sweden Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 51 Sweden Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 52 Sweden Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 53 Asia-Pacific Biomarkers Market, By Country, 2018-2030 (USD Million)
Table 54 Asia-Pacific Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 55 Asia-Pacific Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 56 Asia-Pacific Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 57 Asia-Pacific Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 58 Japan Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 59 Japan Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 60 Japan Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 61 Japan Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 62 China Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 63 China Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 64 China Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 65 China Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 66 India Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 67 India Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 68 India Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 69 India Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 70 South Korea Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 71 South Korea Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 72 South Korea Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 73 South Korea Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 74 Australia Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 75 Australia Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 76 Australia Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 77 Australia Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 78 Thailand Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 79 Thailand Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 80 Thailand Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 81 Thailand Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 82 Latin America Biomarkers Market, By Country, 2018-2030 (USD Million)
Table 83 Latin America Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 84 Latin America Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 85 Latin America Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 86 Latin America Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 87 Brazil Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 88 Brazil Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 89 Brazil Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 90 Brazil Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 91 Argentina Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 92 Argentina Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 93 Argentina Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 94 Argentina Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 95 Mexico Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 96 Mexico Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 97 Mexico Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 98 Mexico Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 99 Middle East and Africa Biomarkers Market, By Country, 2018-2030 (USD Million)
Table 100 Middle East and Africa Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 101 Middle East and Africa Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 102 Middle East and Africa Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 103 Middle East and Africa Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 104 South Africa Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 105 South Africa Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 106 South Africa Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 107 South Africa Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 108 Saudi Arabia Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 109 Saudi Arabia Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 110 Saudi Arabia Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 111 Saudi Arabia Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 112 Kuwait Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 113 Kuwait Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 114 Kuwait Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 115 Kuwait Biomarkers Market, By Disease, 2018-2030 (USD Million)
Table 116 UAE Biomarkers Market, By Type, 2018-2030 (USD Million)
Table 117 UAE Biomarkers Market, By Product, 2018-2030 (USD Million)
Table 118 UAE Biomarkers Market, By Application, 2018-2030 (USD Million)
Table 119 UAE Biomarkers Market, By Disease, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary Interviews in North America
Fig. 5 Primary Interviews in Europe
Fig. 6 Primary Interviews in APAC
Fig. 7 Primary Interviews in Latin America
Fig. 8 Primary Interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Biomarkers market: market outlook
Fig. 14 Tumor ablation competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Biomarkers market driver impact
Fig. 20 Biomarkers market restraint impact
Fig. 21 Biomarkers market strategic initiatives analysis
Fig. 22 Biomarkers market: Type movement analysis
Fig. 23 Biomarkers market: Type outlook and key takeaways
Fig. 24 Safety biomarkers market estimates and forecast, 2018-2030
Fig. 25 Efficacy biomarkers agents estimates and forecast, 2018-2030
Fig. 26 Predictive biomarkers market estimates and forecast, 2018-2030
Fig. 27 Surrogate biomarkers estimates and forecast, 2018-2030
Fig. 28 Pharmacodynamic biomarkers market estimates and forecast, 2018-2030
Fig. 29 Prognostics biomarkers estimates and forecast, 2018-2030
Fig. 30 Validation biomarkers estimates and forecast, 2018-2030
Fig. 31 Biomarkers market: Product movement analysis
Fig. 32 Biomarkers market: Product outlook and key takeaways
Fig. 33 Consumables market estimates and forecast, 2018-2030
Fig. 34 Services estimates and forecast, 2018-2030
Fig. 35 Software market estimates and forecast, 2018-2030
Fig. 36 Biomarkers market: Disease movement analysis
Fig. 37 Biomarkers market: Disease outlook and key takeaways
Fig. 38 Diagnostics market estimates and forecast, 2018-2030
Fig. 39 Drug discovery and development estimates and forecast, 2018-2030
Fig. 40 Personalized medicine market estimates and forecast, 2018-2030
Fig. 41 Disease risk assessment estimates and forecast, 2018-2030
Fig. 42 Others market estimates and forecast, 2018-2030
Fig. 43 Biomarkers market: Disease movement analysis
Fig. 44 Biomarkers market: Disease outlook and key takeaways
Fig. 45 Cancer market estimates and forecast, 2018-2030
Fig. 46 Cardiovascular diseases estimates and forecast, 2018-2030
Fig. 47 Neurological diseases market estimates and forecast, 2018-2030
Fig. 48 Immunological diseases estimates and forecast, 2018-2030
Fig. 49 Others market estimates and forecast, 2018-2030
Fig. 50 Global ophthalmic drugs market: Regional movement analysis
Fig. 51 Global ophthalmic drugs market: Regional outlook and key takeaways
Fig. 52 Global ophthalmic drugs market share and leading players
Fig. 53 North America market share and leading players
Fig. 54 Europe market share and leading players
Fig. 55 Asia-Pacific market share and leading players
Fig. 56 Latin America market share and leading players
Fig. 57 Middle East & Africa market share and leading players
Fig. 58 North America: SWOT
Fig. 59 Europe SWOT
Fig. 60 Asia-Pacific SWOT
Fig. 61 Latin America SWOT
Fig. 62 MEA SWOT
Fig. 63 North America, by country
Fig. 64 North America
Fig. 65 North America market estimates and forecasts, 2018-2030
Fig. 66 U.S. key country dynamics
Fig. 67 U.S. market estimates and forecasts, 2018-2030
Fig. 68 Canada key country dynamics
Fig. 69 Canada market estimates and forecasts, 2018-2030
Fig. 70 Europe
Fig. 71 Europe market estimates and forecasts, 2018-2030
Fig. 72 UK key country dynamics
Fig. 73 UK market estimates and forecasts, 2018-2030
Fig. 74 Germany key country dynamics
Fig. 75 Germany market estimates and forecasts, 2018-2030
Fig. 76 France key country dynamics
Fig. 77 France market estimates and forecasts, 2018-2030
Fig. 78 Italy key country dynamics
Fig. 79 Italy market estimates and forecasts, 2018-2030
Fig. 80 Spain key country dynamics
Fig. 81 Spain market estimates and forecasts, 2018-2030
Fig. 82 Denmark key country dynamics
Fig. 83 Denmark market estimates and forecasts, 2018-2030
Fig. 84 Sweden key country dynamics
Fig. 85 Sweden market estimates and forecasts, 2018-2030
Fig. 86 Norway key country dynamics
Fig. 87 Norway market estimates and forecasts, 2018-2030
Fig. 88 Asia-Pacific
Fig. 89 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 90 China key country dynamics
Fig. 91 China market estimates and forecasts, 2018-2030
Fig. 92 Japan key country dynamics
Fig. 93 Japan market estimates and forecasts, 2018-2030
Fig. 94 India key country dynamics
Fig. 95 India market estimates and forecasts, 2018-2030
Fig. 96 Thailand key country dynamics
Fig. 97 Thailand market estimates and forecasts, 2018-2030
Fig. 98 South Korea key country dynamics
Fig. 99 South Korea market estimates and forecasts, 2018-2030
Fig. 100 Australia key country dynamics
Fig. 101 Australia market estimates and forecasts, 2018-2030
Fig. 102 Latin America
Fig. 103 Latin America market estimates and forecasts, 2018-2030
Fig. 104 Brazil key country dynamics
Fig. 105 Brazil market estimates and forecasts, 2018-2030
Fig. 106 Mexico key country dynamics
Fig. 107 Mexico market estimates and forecasts, 2018-2030
Fig. 108 Argentina key country dynamics
Fig. 109 Argentina market estimates and forecasts, 2018-2030
Fig. 110 Middle East and Africa
Fig. 111 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 112 South Africa key country dynamics
Fig. 113 South Africa market estimates and forecasts, 2018-2030
Fig. 114 Saudi Arabia key country dynamics
Fig. 115 Saudi Arabia market estimates and forecasts, 2018-2030
Fig. 116 UAE key country dynamics
Fig. 117 UAE market estimates and forecasts, 2018-2030
Fig. 118 Kuwait key country dynamics
Fig. 119 Kuwait market estimates and forecasts, 2018-2030
Fig. 120 Market share of key market players- Biomarkers market

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Epigenomics AG
  • General Electric
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • QIAGEN
  • Merck KGaA
  • PerkinElmer Inc.
  • Agilent Technologies, Inc.
  • Eurofins Scientific

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedJanuary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 81.04 Billion
Forecasted Market Value ( USD ) by 2030 $ 194.21 Billion
Compound Annual Growth Rate13.3%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Research Area, Technology (NGS, PCR, Mass Spectrometry), Disease (Cancer, Infectious), Application (Diagnostics, Clinical Research) - Forecast to 2029 - Product Image

Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Research Area, Technology (NGS, PCR, Mass Spectrometry), Disease (Cancer, Infectious), Application (Diagnostics, Clinical Research) - Forecast to 2029

  • Report
  • 507 Pages
  • Global
From
Biomarkers Market by Application (Disease Diagnostics, Drug Discovery, Personalized Medicine), Type (Genomic Biomarkers, Metabolomic Biomarkers, Proteomic Biomarkers), Therapeutic Area, End-users, Biomarker Validation, Technologies - Global Forecast 2025-2030 - Product Image

Biomarkers Market by Application (Disease Diagnostics, Drug Discovery, Personalized Medicine), Type (Genomic Biomarkers, Metabolomic Biomarkers, Proteomic Biomarkers), Therapeutic Area, End-users, Biomarker Validation, Technologies - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Digital Neuro Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile Based Applications), By Clinical Practice, By End Use, By Region And Segment Forecasts, 2024 - 2030 - Product Image

Digital Neuro Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile Based Applications), By Clinical Practice, By End Use, By Region And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Pediatric Cancer Biomarkers Market Size, Share and Trends Analysis Report by Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma), Biomarker (Alpha-Fetoprotein, Neuron-Specific Enolase), End-use 2024-2030 - Product Image

Pediatric Cancer Biomarkers Market Size, Share and Trends Analysis Report by Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma), Biomarker (Alpha-Fetoprotein, Neuron-Specific Enolase), End-use 2024-2030

  • Report
  • 120 Pages
  • Global
From
Biomarker Testing Services Market by Services, Techonology, Disease Area, Application, End-User - Global Forecast 2025-2030 - Product Image

Biomarker Testing Services Market by Services, Techonology, Disease Area, Application, End-User - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.